Merck Financial Statements
NYSE: MRKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:02 PM ET · Delayed 15 min
Merck revenue and earnings
In fiscal 2025, Merck generated $65.01 billion in revenue, up 1.3% from fiscal 2024, its 6th consecutive year of revenue growth. Net income was $18.25 billion (+6.6% year over year), for a net margin of 28.1% versus a median of 24.5% in the prior 5 years. Gross margin was 74.8% (down from 76.3%).
Diluted earnings per share came in at $7.28, up from $6.74. Over the last 5 fiscal years, MRK's revenue has grown at a 9.4% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Merck income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65.01B | 64.17B | 60.12B | 59.28B | 48.70B | 41.52B | 39.12B | 42.29B | 40.12B | 39.81B |
| Revenue growth (YoY) | +1.31% | +6.74% | +1.40% | +21.72% | +17.31% | +6.13% | -7.50% | +5.41% | +0.79% | +0.78% |
| Cost of Revenue | 16.38B | 15.19B | 16.13B | 17.41B | 13.63B | 13.62B | 12.02B | 13.51B | 12.91B | 14.03B |
| Gross Profit | 48.63B | 48.98B | 43.99B | 41.87B | 35.08B | 27.90B | 27.11B | 28.79B | 27.21B | 25.78B |
| Research & Development | 15.79B | 17.94B | 30.53B | 13.55B | 12.24B | 13.40B | 9.72B | 9.75B | 10.34B | 10.26B |
| Selling, General & Admin | 10.73B | 10.82B | 10.50B | 10.04B | 9.63B | 8.96B | 9.46B | 10.10B | 10.07B | 10.02B |
| Interest Expense | 1.36B | 1.27B | 1.15B | 962.00M | 806.00M | 831.00M | 893.00M | 772.00M | 754.00M | 693.00M |
| Other Income (Expense) | -151.00M | 24.00M | -466.00M | -1.50B | 1.34B | 890.00M | -129.00M | 402.00M | 500.00M | -189.00M |
| Pretax Income | 21.07B | 19.94B | 1.89B | 16.44B | 13.88B | 5.86B | 7.17B | 8.70B | 6.52B | 4.66B |
| Income Tax | 2.80B | 2.80B | 1.51B | 1.92B | 1.52B | 1.34B | 1.56B | 2.51B | 4.10B | 718.00M |
| Net Income | 18.25B | 17.12B | 365.00M | 14.52B | 13.05B | 7.07B | 9.84B | 6.22B | 2.39B | 3.92B |
| Net Income growth (YoY) | +6.64% | +4589.59% | -97.49% | +11.27% | +84.65% | -28.20% | +58.25% | +159.82% | -38.93% | -11.75% |
| EPS (Basic) | 7.30 | 6.76 | 0.14 | 5.73 | 5.16 | 2.79 | 3.84 | 2.34 | 0.88 | 1.42 |
| EPS (Diluted) | 7.28 | 6.74 | 0.14 | 5.71 | 5.14 | 2.78 | 3.81 | 2.32 | 0.87 | 1.41 |
| Shares Outstanding (Basic) | 2.50B | 2.53B | 2.54B | 2.53B | 2.53B | 2.53B | 2.56B | 2.66B | 2.73B | 2.77B |
| Shares Outstanding (Diluted) | 2.51B | 2.54B | 2.55B | 2.54B | 2.54B | 2.54B | 2.58B | 2.68B | 2.75B | 2.79B |
| Gross Margin | 74.80% | 76.32% | 73.17% | 70.63% | 72.02% | 67.20% | 69.29% | 68.06% | 67.82% | 64.75% |
| Net Margin | 28.08% | 26.68% | 61.00% | 24.49% | 26.79% | 17.02% | 25.16% | 14.71% | 5.97% | 9.85% |
This table shows 10 annual periods of Merck's income statement, from FY 2025 back to FY 2016, across 16 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow MRK's reporting calendar. What is a income statement?